Fed Circuit affirms generic maker’s win over Eagle
11-05-2020
Teva and Mylan implore Fed Circuit not to stay immunity ruling
07-11-2018
Bill Perry / Shutterstock.com
The US Court of Appeals for the Federal Circuit has narrowed the landscape in which patent infringement suits over generic drugs suits can be filed, in a ruling handed down yesterday, November 5.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Federal Circuit, patents, generic, venue, Mylan, MPI, Valeant, Dow, Kaken, Hatch-Waxman Act
